Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm

According to a federal securities lawsuit, Insiders at Rocket Pharmaceuticals caused the company to provide investors with material information concerning Rocket's Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease. The statements included, among other things, confidence in the drug's safety and efficacy, as well as the clinical trial's detailed protocol and Rocket's purported ability to meet the trial's endpoints as per the Company's ascribed timeline. While, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RPA501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders.